TY - JOUR
T1 - Efficacy of catheter ablation for atrial arrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy—a multicenter study
AU - Gasperetti, Alessio
AU - James, Cynthia A.
AU - Chen, Liang
AU - Schenker, Niklas
AU - Casella, Michela
AU - Kany, Shinwan
AU - Mathew, Shibu
AU - Compagnucci, Paolo
AU - Müssigbrodt, Andreas
AU - Jensen, Henrik K.
AU - Svensson, Anneli
AU - Costa, Sarah
AU - Forleo, Giovanni B.
AU - Platonov, Pyotr G.
AU - Tondo, Claudio
AU - Song, Jiang Ping
AU - Russo, Antonio Dello
AU - Ruschitzka, Frank
AU - Brunckhorst, Corinna
AU - Calkins, Hugh
AU - Duru, Firat
AU - Saguner, Ardan M.
N1 - Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/11/1
Y1 - 2021/11/1
N2 - Background: Atrial arrhythmias are present in up to 20% of patients with arrhythmogenic right ventricular cardiomyopathy (ARVC). Catheter ablation (CA) is an effective treatment for atrial arrhythmias in the general population. Data regarding CA for atrial arrhythmias in ARVC are scarce. Objective: To assess the safety and efficacy of CA for atrial arrhythmias in patients with ARVC. Methods: In this international collaborative effort, all patients with a definite diagnosis of ARVC undergoing CA for atrial fibrillation (AF), focal atrial tachycardia (AT), or cavotricuspid isthmus (CTI)‐dependent atrial flutter (AFl) were extracted from twelve ARVC registries. Demographic, periprocedural, and long‐term arrhythmic outcome data were collected. Results: Thirty‐seven patients were enrolled in the study (age 50.2 ± 16.6 years, male 84%, CHA2DS2VASc 1 (1,2), HAS‐BLED 0 (0–2)). The arrhythmia leading to CA was AF in 23 (62%), focal left AT in 5 (14%), and CTI‐dependent AFl in 9 (24%). Acute procedural success was achieved in all procedures but one (n = 1 focal left AT; 97% acute success). The median follow‐up period was 27 (13–67) months, and 96%, 74%, and 61% of patients undergoing AF ablation were free from any atrial arrhythmia recurrence after a single procedure at 6 months, 12 months, and last follow‐up, respectively. After focal AT ablation, freedom from atrial arrhythmia recurrence was 80%, 80%, and 60% at 6 months, 12 months, and last follow‐up, respectively. All patients undergoing CTI ablation were free from atrial arrhythmia recurrences at 6 months, with 89% single‐procedural arrhythmic freedom at last follow‐up. One major complication (2.7%; PV stenosis requiring PV stenting) occurred. Conclusions: CA is safe and effective in managing atrial arrhythmias in patients with ARVC, with success rates comparable to the general population.
AB - Background: Atrial arrhythmias are present in up to 20% of patients with arrhythmogenic right ventricular cardiomyopathy (ARVC). Catheter ablation (CA) is an effective treatment for atrial arrhythmias in the general population. Data regarding CA for atrial arrhythmias in ARVC are scarce. Objective: To assess the safety and efficacy of CA for atrial arrhythmias in patients with ARVC. Methods: In this international collaborative effort, all patients with a definite diagnosis of ARVC undergoing CA for atrial fibrillation (AF), focal atrial tachycardia (AT), or cavotricuspid isthmus (CTI)‐dependent atrial flutter (AFl) were extracted from twelve ARVC registries. Demographic, periprocedural, and long‐term arrhythmic outcome data were collected. Results: Thirty‐seven patients were enrolled in the study (age 50.2 ± 16.6 years, male 84%, CHA2DS2VASc 1 (1,2), HAS‐BLED 0 (0–2)). The arrhythmia leading to CA was AF in 23 (62%), focal left AT in 5 (14%), and CTI‐dependent AFl in 9 (24%). Acute procedural success was achieved in all procedures but one (n = 1 focal left AT; 97% acute success). The median follow‐up period was 27 (13–67) months, and 96%, 74%, and 61% of patients undergoing AF ablation were free from any atrial arrhythmia recurrence after a single procedure at 6 months, 12 months, and last follow‐up, respectively. After focal AT ablation, freedom from atrial arrhythmia recurrence was 80%, 80%, and 60% at 6 months, 12 months, and last follow‐up, respectively. All patients undergoing CTI ablation were free from atrial arrhythmia recurrences at 6 months, with 89% single‐procedural arrhythmic freedom at last follow‐up. One major complication (2.7%; PV stenosis requiring PV stenting) occurred. Conclusions: CA is safe and effective in managing atrial arrhythmias in patients with ARVC, with success rates comparable to the general population.
KW - Ablation in special populations
KW - Arrhythmogenic right ventricular cardiomyopathy
KW - Atrial fibrillation
KW - Atrial flutter
KW - Pulmonary vein isolation
U2 - 10.3390/jcm10214962
DO - 10.3390/jcm10214962
M3 - Article
C2 - 34768482
AN - SCOPUS:85117907080
SN - 2077-0383
VL - 10
JO - Journal of Clinical Medicine
JF - Journal of Clinical Medicine
IS - 21
M1 - 4962
ER -